Insomnia Treatment Drugs Market

Report Overview

The global insomnia treatment drugs market was pegged at US$ 2.8 in 2021 and is expected to witness a CAGR of 4.2% during the forecast period.

Market Fundamentals 

Insomnia is a sleep disorder characterized by difficulty to fall or remain asleep, which potentially causes serious health problems. According to the CDC (Centers for Disease Control and Prevention), adults from age 18 to 60 need at least 7+ more hours of sleep. Insomnia affects health, body energy level, work performance, mood, and overall quality of life. Research has found that insufficient sleep is linked to an increased risk for the development of type 2 diabetes, and cardiovascular diseases, notably, hypertension, stroke, coronary heart disease, and irregular heartbeats. At some point, many people experience acute insomnia which lasts at least for days or weeks, others may experience long-term (chronic) insomnia that lasts for a month or more. There are two types of insomnia: primary and secondary. Primary insomnia related to sleep problems are not linked to any other health condition or problem; secondary insomnia is related to sleeping trouble because of an underlying health condition (like asthma, arthritis, cancer depression, or heartburn) pain, medication, or substance use (alcohol or narcotics). 

Market Dynamics

The global insomnia treatment drugs market is mainly driven by rising stress-related events like long hours of working, mental health, sensitivity to light and sound, changes in sleeping schedule, family history of insomnia, growing geriatric population, and increasing awareness about various treatment options. However, continuous use of insomnia drugs may cause addiction, dependency and higher adoption of generic products that are available at a cheaper price is negatively affecting the growth of the insomnia treatment drugs market. The availability of alternatives to insomnia drug like antipsychotics, tricyclic antidepressants, chloral derivatives, and herbal supplements are restraining the market growth.

Market Ecosystem

The global insomnia treatment drugs markethas been analyzed from four perspectives: Drug, Formulation, Type of Insomnia, and Region. 

Insomnia Treatment Drugs market by Drug

Based on drug types, the global insomnia treatment drugs market has been segmented into Sedative-Hypnotics, Antidepressants, antihistamines, and others. The sedative hypnotics are classified as barbiturates, benzodiazepines and nonbenzodiazepine hypnotics. The sedative hypnotics segment is leading the global insomnia treatment drugs market owing to its benefits used for the treatment of various diseases like mental issues, psychotic disorders, sleep disorders and Alzheimer's disease. Additionally,  instant therapeutic effect, increases sleep duration and stops night awakenings are some of the factor that contributing growth of this market. 

Insomnia Treatment Drugs Market by Formulation

Based on formulation, the insomnia treatment drugs market has been segmented into tablets, capsules, and others. Tablets are expected to hold the highest share during the forecast period. Drugs in tablet form are in high demand as tablets are more stable than other drug formulations, easy for consumption, have high dose accuracy and have low cost of manufacturing. Capsules had also shown growth demand as they have been used to mask the taste and odor of API. 

Insomnia treatment drugs market by Type of Insomnia

Based on the type of disease, the insomnia market has been segmented into adjustment insomnia, behavioral insomnia of childhood, idiopathic insomnia, inadequate sleep hygiene, insomnia due to drug or substance, medical condition, or mental disorder, paradoxical insomnia, and psychophysiological insomnia. Among these, adjustment insomnia dominates the insomnia treatment drugs market with the highest share during the forecast period. The growth of the segment can be attributed to the increasing patient base, rampant work timings, mental health instability, stress, and hypertension.

Insomnia Treatment Drugs Market by Region

Based on region, the global insomnia treatment drugs market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America leads the insomnia drug treatment market in terms of revenue. Driving factor for the dominance of this market is rising cases of sleeping disorders in this region, and awareness about the management of sleeping disorders. In May 2022, US Sleep Foundation stated average of 35.2% of all adults in US get sleeps less than seven hours per night. Insomnia is caused by prescription drugs, medical disorders, stress, abnormal health conditions and substance abuse. In July 2019, Zydus Cadila launches the drug Ramelteon in the US market for treatment of insomnia. In May 2022, Idorsia launched QUVIVIQ (daridorexant) a new treatment for insomnia and its now available in the US for adults living with insomnia. Thus, frequent product launches is also indicative of growth of the insomnia treatment drugs market in North America.

Competitive Landscape

Some of the prominent players operating in the global insomnia treatment drugs market are 

• Heptares Therapeutics (Sosei Group Corporation)
• Meda Consumer Healthcare Inc. (U.S.)
• Takeda Pharmaceutical Company Ltd. (Japan)
• Evotec
• Eisai
• Pernix Therapeutics (U.S.)
• Merck
• Astellas Pharma
• Alexza Pharmaceuticals (Ferrer Therapeutics, Inc.)
• Zydus Cadila

Strategic Developments

• In April 2022, Evotec announced positive outcomes for Phase I and Phase II clinical trial for insomnia treatment.
• In June 2021, Eisai Co., Ltd. announced that its U.S. subsidiary Eisai Inc. had launched its in-house discovered orexin receptor antagonist DAYVIGO™ (lemborexant) CIV for the treatment of adults with insomnia.
• In Jun 2020, 3Z Pharmaceutical received $ 2 million in funding for the preclinical development of novel insomnia and ADHD therapeutic.
• In Feb 2019, Sosei Heptares Corporation entered into a financing agreement with Medicxi to invest up to € 40 million in new collaboration based on its Orexin agonist program 

Frequently Asked Questions About This Report